Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has announced that two of its studies regarding its application in oncology drug development and personalized medicine have been selected for a poster and oral presentation at the upcoming AACR-EORTC conference in Boston.
A poster will be presented by Dr. Elizabeth Bruckheimer, Champions' Vice President for Scientific Operations, which will detail the Biomerk Tumorgraft(TM) platform and its characterization. Together the results demonstrate that by maintaining the fundamental genotypic features of the original tumor along with the stromal and cancer stem cell components, the Biomerk Tumorgraft enables identification of the most promising development path for a compound in terms of indication, drug combination, and target patient populations. The platform also has the potential to identify gene pathways of response and resistance as well as prognostic molecular biomarkers. The banking and characterization efforts are performed in collaboration with South Texas Accelerated Research Therapeutics (START).
"The predictive power of the Biomerk Tumorgraft platform is very exciting," said Dr. Bruckheimer. "Application of our models to translational drug development is demonstrating great promise in streamlining the development path of our biotech and pharma partners by giving them a more focused, accelerated and higher probability translational path in clinical trials. Additionally, we are using our platform to build our own oncology pipeline which we expect to yield improved clinical development success rates. We believe that this platform will continue to change the way in which oncology drugs are developed, and oncology patients are treated."